Scleroderma Awareness Month creates a focused opportunity to improve recognition, access, and support.
Scleroderma Awareness Month 2026: Build One Connected Specialty Pathway
- Posted by Greg Wahlstrom, MBA, HCM
- Posted in 2026 Healthcare Observances Calendar, Health Observance Calendar
Skip to the executive brief
June
June 29
Many systems
Stage 01
Stage 02
Stage 03
Stage 04
Stage 05
Executive Rare Disease Operating Brief
Scleroderma Awareness Month 2026: Build One Connected Specialty Pathway
Use June to improve recognition, rheumatology access, organ-risk surveillance, coordinated treatment, rehabilitation, behavioral support, and longitudinal partnership.
The leadership signal: complexity requires coordination, not repeated navigation
June is Scleroderma Awareness Month, culminating in World Scleroderma Day on June 29. The National Scleroderma Foundation’s 2026 campaign calls attention to a rare autoimmune disease that can affect the skin and connective tissues and, in systemic forms, the lungs, heart, kidneys, gastrointestinal tract, blood vessels, and other organs.
Scleroderma is not one uniform condition. Localized forms primarily affect the skin and nearby tissues. Systemic sclerosis can involve internal organs, but the pattern, pace, and severity vary. Symptoms may include skin thickening or tightness, Raynaud phenomenon, digital ulcers, reflux or swallowing difficulty, pain, fatigue, joint limitations, breathing symptoms, and other concerns. Diagnosis may be delayed because early symptoms can resemble more common problems.
For executives, the failure mode is fragmentation. A patient may move among primary care, emergency services, rheumatology, pulmonology, cardiology, nephrology, gastroenterology, dermatology, wound care, rehabilitation, pharmacy, behavioral health, and community resources. When every specialty manages only its portion, important trends can be missed, testing is duplicated, medication risks become harder to see, and the patient becomes the default care coordinator.
Three facts that should shape the 2026 response
World Scleroderma Day emphasizes awareness, advocacy, research, and the lives of people affected.
Systemic sclerosis may affect multiple organs, requiring risk-based surveillance and coordinated care.
Scleroderma can occur in people of any background. Women are affected more often than men, but population patterns should not become diagnostic shortcuts. Race, geography, access to specialists, insurance, disability, language, and socioeconomic conditions may influence delay and outcomes. Leaders should monitor their own data and avoid assuming that a rare disease will present in a “typical” patient.
There is no single screening test or one treatment for every person. Diagnosis combines history, examination, laboratory evaluation, and other studies guided by clinical findings. Treatment aims to control specific manifestations, prevent or limit organ damage, preserve function, and improve quality of life. The operating model must respond to risk without subjecting every patient to identical care.
Build one pathway from recognition to lifelong partnership
A reliable pathway captures the whole picture. It documents symptom onset, Raynaud phenomenon, skin and vascular findings, function, pain, breathing and gastrointestinal symptoms, blood pressure and kidney concerns, medication exposure, pregnancy goals when relevant, work and home barriers, mental health, and patient priorities. It also defines which changes require urgent review.
Recognize
Identify concerning patterns and create a clear referral route.
Assess
Confirm the condition and establish organ-specific baselines.
Stratify
Match surveillance and urgency to subtype, findings, and change.
Coordinate
Align specialty treatment, pharmacy, rehabilitation, and support.
Partner
Track outcomes and respond to new symptoms over time.
Urgent escalation should be explicit. New or worsening shortness of breath, chest pain, fainting, abrupt severe blood-pressure elevation, acute kidney concerns, rapidly worsening digital ischemia or infection, and other serious changes require prompt clinical assessment based on the situation. Patients should receive plain-language guidance about who to call and where to go.
Six executive decisions that turn awareness into reliable care
1. Create rapid recognition and referral standards
Give primary, urgent, emergency, dermatology, vascular, and community clinicians a clear route to rheumatology advice. Include Raynaud patterns, skin change, digital complications, swallowing concerns, respiratory symptoms, and other findings. Define urgency, required information, and what to do when specialty capacity is limited.
2. Standardize baseline and surveillance workflows
Use current clinical guidance to define patient-specific assessment of pulmonary, cardiovascular, renal, gastrointestinal, musculoskeletal, vascular, and skin involvement. Track due care and abnormal results. Do not rely on the patient to connect a pulmonary-function trend in one clinic with a medication decision in another.
3. Build a multidisciplinary review model
Create a practical structure for rheumatology, pulmonology, cardiology, nephrology, gastroenterology, dermatology, pharmacy, rehabilitation, nursing, behavioral health, and primary care. The model may use a clinic, conference, shared plan, or virtual consultation. The essential outcome is unified decision-making and ownership.
4. Strengthen medication and treatment safety
Maintain one reconciled medication list, indication, monitoring plan, and prescriber responsibility. Flag therapies or common medications that may create special risks in systemic sclerosis. Coordinate immunization, infection prevention, laboratory monitoring, reproductive counseling when applicable, affordability, and rapid response to adverse effects.
5. Protect function and participation
Integrate occupational and physical therapy, hand function, oral health, nutrition, swallowing support, pain management, fatigue strategies, wound care, behavioral health, and workplace accommodation. Measure activities that matter to the patient, not only organ tests. Offer care that supports autonomy rather than defining the person by limitation.
6. Connect expertise across geography
Rare-disease expertise may be concentrated. Use referral agreements, e-consults, telehealth where appropriate, image and test exchange, local monitoring, and shared-care protocols. Track travel burden and abandoned referrals. A referral to a distant center is not access unless the patient can complete it.
Build care around the person, not the organ list
Scleroderma may change appearance, mobility, eating, sleep, intimacy, work, social connection, and confidence. The burden can remain invisible when visits focus only on laboratory and imaging results. Ask patients what has changed, what they fear, what they want to preserve, and which part of the care plan is hardest to carry out.
Provide accessible education, qualified interpretation, peer-support options, financial navigation, and a consistent contact. Include family or caregivers with permission. Screen for depression, anxiety, and distress without treating them as explanations for physical symptoms. Respect uncertainty and avoid promises that one treatment or wellness practice can “cure” a complex autoimmune disease.
Put specialty-pathway reliability on the executive scorecard
| Domain | Core measure | Executive question |
|---|---|---|
| Recognition | Time from documented concerning pattern to rheumatology review | Where does a rare diagnosis become a long delay? |
| Baseline assessment | Risk-appropriate organ evaluation completed and reviewed | Are abnormal findings assigned to an owner? |
| Surveillance | Due tests and visits completed within the defined interval | Who is lost between specialties? |
| Coordination | High-risk patients with one current multidisciplinary plan | Does every clinician act from the same priorities? |
| Safety | Medication reconciliation, monitoring, and urgent escalations completed | Can the pathway detect harm early? |
| Function and experience | Patient-reported function, symptoms, burden, and goals | Are we improving life as well as test results? |
| Equity | Access and outcomes stratified by population and geography | Who cannot reach expertise or sustain follow-up? |
Use balanced measures. More testing is not automatically safer if results lack ownership or create avoidable burden. Fewer emergency visits may reflect better care, or they may reflect access loss. Combine clinical data with patient-reported outcomes, medication safety review, care-navigation data, and lived-experience input.
A 90-day activation plan
Days 1 to 30: Map
- Name an executive sponsor and pathway owner.
- Map referral, baseline assessment, surveillance, and escalation.
- Audit specialty waits, abandoned referrals, and duplicated testing.
- Listen to patients, caregivers, and frontline teams.
Days 31 to 60: Test
- Run dyspnea, renal-risk, digital-ulcer, transfer, and rural-access scenarios.
- Test shared-plan visibility and result ownership.
- Review medication monitoring and affordability.
- Audit rehabilitation and behavioral-health access.
Days 61 to 90: Scale
- Publish referral, surveillance, and escalation standards.
- Launch the dashboard with equity and function measures.
- Formalize referral-center and local-care agreements.
- Continue governance after June 29.
Conclusion: make rare-disease expertise work as one system
Scleroderma Awareness Month 2026 should help people recognize a complex disease, but awareness alone does not solve the operational problem. Patients need timely expertise, organ-risk surveillance, coordinated decisions, medication safety, rehabilitation, accessible support, and a plan that remains coherent across years and settings.
The executive mandate is to remove avoidable fragmentation. Name the owner, connect the specialists, close result loops, define urgent routes, measure function, and bring expertise closer through shared care. When the organization coordinates around the person, rare-disease care becomes safer, more equitable, and more humane.
Authoritative resources
Awareness and patient information
Clinical note: New severe respiratory, chest, renal, neurological, vascular, or infectious symptoms may require urgent evaluation. Practice note: This executive brief supports operational planning and does not replace patient-specific assessment, current specialty guidance, emergency evaluation, or organizational counsel.
